Favorable prognostic value of SOCS2 and IGF-I in breast cancer. - Wikidata - wikimedia - TriplyDB

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

http://www.wikidata.org/entity/Q33291671

about

Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases The role of suppressors of cytokine signalling in human neoplasms Signal transducer and activator of transcription 5A/B in prostate and breast cancers Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer.Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer.Suppressor of cytokine signaling-2 gene disruption promotes Apc(Min/+) tumorigenesis and activator protein-1 activation Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma Physical confirmation and mapping of overlapping rat mammary carcinoma susceptibility QTLs, Mcs2 and Mcs6 Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer.High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer.Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity.Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.Differential Expression of Ccn4 and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells.SOCS proteins in development and disease.Differential gene expression of the key signalling pathway in para-carcinoma, carcinoma and relapse human pancreatic cancer.Molecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy.The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells Infiltrating CD11b+CD11c+ cells have the potential to mediate inducible nitric oxide synthase-dependent cell death in mammary carcinomas of HER-2/neu transgenic mice.Alterations in the p53-SOCS2 axis contribute to tumor growth in colon cancer.Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis.The prognostic significance of the insulin-like growth factor-1 ligand and receptor expression in breast cancer tissue.

P2860

Q24656365-7D36479E-AC34-4C4B-AFAE-CD3E82D586FE Q27026783-727BACA8-DD9B-45C0-A8AF-4A04F2E39D3A Q28281791-D4BC4085-9962-4CD3-AF6B-69238594851B Q33569316-B79EC5EA-9B75-4773-83C7-3CCD1B899A91 Q33611598-6EDF401A-A07F-402A-9955-04E4140D3E00 Q33810288-F5360D62-AD81-4C44-A05B-EE6F638A58D4 Q33816368-959FBAD5-9D47-4674-AB61-94DF806A06AF Q33911829-F7A1AD8B-FC5B-4138-A812-D29AECDE63F6 Q33916825-40E291F2-8648-4279-9E52-DFCA61A39A42 Q34051993-F11CA103-D546-44C8-B5F7-C688AAD516F5 Q34845224-5602AC10-D4C0-432C-A2E5-74A0A18F14DD Q35628188-3210E1C6-DBB4-4DBC-A70B-17FD7F7EE10E Q35683515-3F9F8C17-458D-4AF9-9DD1-B84E8014E7E6 Q35737909-D94EF1E2-DA14-4BA6-8C03-C36A1349B27A Q37402199-D896E29E-2EF9-4351-8F5E-E34DB72F599B Q37418923-C9144384-84E2-4023-B785-9191EDA1D5E2 Q37569984-323394F3-BDF0-47EA-9220-11FA23A6B020 Q38124037-CE427813-65AA-4E89-AE31-99BE3296486A Q38484647-AA5721C4-E077-43B4-8F5A-C9E0F73C6666 Q38500301-3EC9B0F6-17D8-4FCB-B29F-20B600E6217F Q39764749-87FB05B5-C458-4473-A9DA-32C6720F91DA Q39816984-69C414B2-935D-483F-ABA6-A38D58E9776F Q52721250-848A89B8-CAF8-49EF-AEF0-D420E27DCB1B Q54269263-37793CB1-1848-42BE-A481-814ED04C5831 Q54378660-C2CBB1F9-57DE-490F-AF4F-E0CC57DEB6D7

P2860

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

http://www.wikidata.org/entity/Q33291671

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

@ast

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

@en

type

label

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

@ast

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

@en

prefLabel

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

@ast

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

@en

P1433

Q33291671-B88243AB-B17C-4500-BEBA-7781062B923A

P1476

Q33291671-BBAA32A8-2DD2-4781-A197-37AF130A368E

P2093

Q33291671-0D089504-FE70-4AD7-8FDB-7C962B6CE11F

Q33291671-14BBA733-CDD1-4F76-B007-75B0EF871D56

Q33291671-25BFDB1B-D36A-430A-8E03-98C0F48E9DD3

Q33291671-2B2CC61A-34F3-4DEC-BD51-C9D426424EFB

Q33291671-31343E20-D2B3-4BDF-BDC3-68CCF3120181

Q33291671-B6A5FE26-E26C-46F6-9C8F-26FAC604CA7B

Q33291671-CEE4E159-94A3-4AA5-BDDC-C0D9BF5E2AD0

Q33291671-E9B1C1F8-A11D-425B-A929-C0877B3C55EC

P2860

Q33291671-06F109C6-983D-4B34-AF3F-BCF9FC66F66E

Q33291671-08063FD4-7F20-4AB7-B96F-A0894D864CFB

Q33291671-0C6B18A0-0E09-4AE6-A5F3-36453BE2D065

Q33291671-0CFBD44C-7AC1-4349-B4B4-0AACF684EC28

Q33291671-1376C888-A463-48FD-962F-7F3AD6E0187C

Q33291671-150F247A-22F6-4786-857A-EA01E57233C0

Q33291671-16F6D94E-A8AF-4EAD-B5E7-8A6FA9356615

Q33291671-1704F90C-1C2F-463F-BDF7-EB2A12C20AA0

Q33291671-1FFD5399-2E15-4322-BBDC-1311F946A119

Q33291671-216827F5-7BE9-41EB-B808-F7DCD2D0E723

P2888

Q33291671-D5DE4AEF-35FE-4894-9D57-E47E311322E1

P304

Q33291671-2338AF3B-BCE7-4EB5-8133-A4903FBC2C3C

P31

Q33291671-5A7534CC-384F-461D-9AA0-643189C1F48E

P356

Q33291671-09025583-D093-48CB-A277-0F2123945E9B

P407

Q33291671-2FDE6289-0B26-4F1F-AF00-A91F78952B10

P478

Q33291671-6AFAF9BB-1034-4965-BA15-84EAE8DA0F66

P577

Q33291671-D75894F6-25D8-48EE-9202-283C525A7CB5

P5875

Q33291671-745FE927-26BD-4FC6-9C2B-E2BCFA620D3D

P6179

Q33291671-4E897603-9DCC-41AE-B350-DD61888A2DD4

P698

Q33291671-7BAF768A-7FCC-4744-9AF7-27FB0F4EEAAC

P932

Q33291671-1E0DA084-BDBC-4E81-8469-2834BA5737E4

P356

1471-2407-7-136

P1433

P1476

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

@en

P2093

Barbara Petridou

http://www.w3.org/2001/XMLSchema#string

Christian Marth

http://www.w3.org/2001/XMLSchema#string

Elisabeth Müller-Holzner

http://www.w3.org/2001/XMLSchema#string

Françoise Révillion

http://www.w3.org/2001/XMLSchema#string

Günter Daxenbichler

http://www.w3.org/2001/XMLSchema#string

Jean Phillipe Peyrat

http://www.w3.org/2001/XMLSchema#string

Michael C Haffner

http://www.w3.org/2001/XMLSchema#string

Wolfgang Doppler

http://www.w3.org/2001/XMLSchema#string

P2860

Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2

Cloning and characterization of novel CIS family genes

Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation

A gene-expression signature as a predictor of survival in breast cancer

Gigantism in mice lacking suppressor of cytokine signalling-2

SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2

Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b)

SOCS2 negatively regulates growth hormone action in vitro and in vivo

Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses

SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer

P2888

1471-2407-7-136

P304

136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-7-136

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2007-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6188192

http://www.w3.org/2001/XMLSchema#string

P6179

1036896024

http://www.w3.org/2001/XMLSchema#string

P698

17651480

http://www.w3.org/2001/XMLSchema#string

P932

1948006

http://www.w3.org/2001/XMLSchema#string